Zhang Shai-Lin, Mao Ning-Fang, Sun Jun-Ying, Shi Zhi-Cai, Wang Bing, Sun Yong-Jian
Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, China.
Asian Pac J Cancer Prev. 2012;13(6):2705-9. doi: 10.7314/apjcp.2012.13.6.2705.
To evaluate the predictive value of glutathione S-transferase (GST) gene polymorphisms for the prognosis of osteosarcoma patients receiving chemotherapy.
A total of 159 patients were included in our study between January 2005 and December 2007., with follow-up until January 2012. Genotyping was based upon the duplex polymerase-chain-reaction with the PCR-CTPP method.
At the time of diagnosis, 15.4% of the patients presented with metastasis, while 22.3% developed metastasis during follow-up. At the time of final analysis on January 2012, the median follow-up was 45.5 months. Patients with null GSTM1 and GSTT1 had a higher event free survival rate than non-null genotype, but no significant association was found between the two genotypes and prognosis of osteosarcoma. Individuals with GSTP1 Val/Val genotype tended to live shorter than with the IIe/IIe genotype, and we found a significantly higher risk of death from osteosarcoma (adjusted HR=2.35, 95% CI=1.13-4.85).
The GSTP1 gene polymorphism may have an important role in the prognosis of osteosarcoma patients with chemotherapy. Further analyses with larger samples and more genes encoding metabolizing and DNA repair enzymes are warranted.
评估谷胱甘肽S-转移酶（GST）基因多态性对接受化疗的骨肉瘤患者预后的预测价值。
2005年1月至2007年12月期间，共有159例患者纳入本研究，并随访至2012年1月。基因分型采用PCR-CTPP法的双重聚合酶链反应。
诊断时，15.4%的患者出现转移，而22.3%的患者在随访期间发生转移。在2012年1月进行最终分析时，中位随访时间为45.5个月。GSTM1和GSTT1基因缺失的患者无事件生存率高于非缺失基因型，但未发现这两种基因型与骨肉瘤预后之间存在显著关联。GSTP1 Val/Val基因型个体的生存期往往短于Ile/Ile基因型个体，且我们发现骨肉瘤死亡风险显著更高（校正风险比=2.35，95%置信区间=1.13-4.85）。
GSTP1基因多态性可能在接受化疗的骨肉瘤患者的预后中起重要作用。有必要对更大样本和更多编码代谢及DNA修复酶的基因进行进一步分析。
